Oligonucleotide CDMO Market: Global Forecast to 2031

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN OLIGONUCLEOTIDES CDMO MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3.1 OLIGONUCLEOTIDE CDMO MARKET OVERVIEW
3.2 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE
3.3 OLIGONUCLEOTIDE CDMO MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 OLIGONUCLEOTIDE CDMO MARKET SHARE, BY SERVICE TYPE, 2026 VS. 2031

4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Growing demand for Pre-Clinical-to-Commercial oligo CDMOs
4.2.1.2 Increase in CDMO partnerships for scalability
4.2.1.3 Increasing focus on precision/personalized medicine
4.2.2 RESTRAINTS
4.2.2.1 Complexities associated with therapeutic oligonucleotide manufacturing
4.2.3 OPPORTUNITIES
4.2.3.1 Increasing use of oligos in CRISPR-Cas9 applications
4.2.3.2 Expansion of oligonucleotide therapeutics into cardiometabolic and common chronic diseases
4.2.4 CHALLENGES
4.2.4.1 Lack of sustainable supply chain
4.2.4.2 Limited scalability of GMP oligonucleotide synthesis
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 INTENSITY OF COMPETITIVE RIVALRY
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 THREAT OF NEW ENTRANTS
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
5.5 KEY CONFERENCES & EVENTS, 2026-2027
5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.7 INVESTMENT & FUNDING SCENARIO
5.8 IMPACT OF 2025 US TARIFF ON OLIGONUCLEOTIDE CDMO MARKET
5.8.1 INTRODUCTION
5.8.2 KEY TARIFF RATES
5.8.3 PRICE IMPACT ANALYSIS
5.8.4 IMPACT ON COUNTRY/REGION
5.8.4.1 US
5.8.4.2 Europe
5.8.4.3 Asia Pacific
5.8.5 IMPACT ON END-USE INDUSTRIES
5.8.5.1 Pharmaceutical & Biotechnology Companies
5.8.5.2 Diagnostic companies
5.8.5.3 Other end users

6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY TECHNOLOGIES
6.1.1.1 Process technologies
6.1.1.1.1 Solid-phase synthesis
6.1.1.1.2 Liquid-phase synthesis
6.1.1.1.3 Enzymatic phase synthesis
6.1.1.2 Purification, analysis, and quality control technologies
6.1.1.2.1 Affinity chromatography
6.1.1.2.2 Tangential flow filtration (tff) & ultrafiltration
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Polymerase chain reaction (PCR)
6.1.2.2 Next-generation sequencing (NGS)
6.1.2.3 Microarray technology/hybridization-based assays
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Galnac conjugation/Antibody-oligonucleotide conjugation
6.1.3.2 Lipid nanoparticle (LNP) encapsulation
6.2 TECHNOLOGY ROADMAP
6.3 FUTURE APPLICATIONS
6.4 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET
6.4.1 TOP USE CASES AND MARKET POTENTIAL
6.4.2 BEST PRACTICES IN AI-ENABLED OLIGONUCLEOTIDE CDMO WORKFLOWS
6.4.3 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE CDMO MARKET
6.4.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.4.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED OLIGONUCLEOTIDE CDMO TECHNOLOGIES

7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Rest of the World
7.2 SUSTAINABILITY INITIATIVES
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS

8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9.1 INTRODUCTION
9.2 CONTRACT MANUFACTURING
9.2.1 COMMERCIAL STAGE
9.2.1.1 Advancing oligonucleotide therapies and demand for reliable commercial-scale GMP supply are driving growth in commercial-stage services
9.2.2 CLINICAL STAGE
9.2.2.1 Advancing clinical pipelines and demand for specialized scalable manufacturing are driving growth in clinical-stage services
9.3 CONTRACT DEVELOPMENT
9.3.1 INCREASINGLY COMPLEX OLIGONUCLEOTIDE PIPELINES AND DEMAND FOR OPTIMIZED CLINICAL MANUFACTURING PROCESSES ARE DRIVING CONTRACT DEVELOPMENT GROWTH
9.4 OTHER SERVICES
9.4.1 INCREASING MOLECULAR COMPLEXITY AND DEMAND FOR INTEGRATED ANALYTICAL AND DRUG-PRODUCT SUPPORT ARE DRIVING GROWTH IN OTHER SERVICES

10.1 INTRODUCTION
10.2 THERAPEUTIC APPLICATIONS
10.2.1 EXPANDING THERAPEUTIC APPLICATIONS AND ADVANCING OLIGONUCLEOTIDE PIPELINES ARE DRIVING DEMAND FOR SPECIALIZED CDMO SERVICES.
10.3 RESEARCH APPLICATIONS
10.3.1 EXPANDING GENOMICS, SEQUENCING, CRISPR RESEARCH, AND OUTSOURCED CUSTOM SYNTHESIS DRIVE GROWTH
10.4 DIAGNOSTIC APPLICATIONS
10.4.1 EXPANDING MOLECULAR DIAGNOSTICS AND PRECISION ONCOLOGY DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE MANUFACTURING

11.1 INTRODUCTION
11.2 ANTISENSE OLIGONUCLEOTIDE (ASO)
11.2.1 ADVANCING ASO PIPELINES AND INCREASING DEMAND FOR SCALABLE GMP MANUFACTURING ARE DRIVING GROWTH
11.3 SMALL INTERFERING RNA (SIRNA)
11.3.1 EXPANDING SIRNA PIPELINES AND INCREASING DEMAND FOR SPECIALIZED GMP MANUFACTURING ARE DRIVING GROWTH IN THE MARKET.
11.4 OTHER OLIGONUCLEOTIDES
11.4.1 EXPANDING CRISPR AND TARGETED APTAMER APPLICATIONS DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE CDMO CAPABILITIES

12.1 INTRODUCTION
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.2.1 EXPANDING NUCLEIC ACID PIPELINES AND INCREASING OUTSOURCING DRIVE PHARMACEUTICAL AND BIOTECHNOLOGY DEMAND FOR CDMO SERVICES
12.3 DIAGNOSTIC COMPANIES
12.3.1 RISING MOLECULAR TESTING AND DEMAND FOR COMPLIANT CUSTOM OLIGOS DRIVE DIAGNOSTIC OUTSOURCING
12.4 OTHER END USERS

13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 US
13.2.1.1 Expanding domestic GMP capacity and increasing outsourcing are driving US oligonucleotide CDMO growth.
13.2.2 CANADA
13.2.2.1 Integrated North American manufacturing networks and growing outsourcing demand are supporting Canada’s oligonucleotide CDMO market
13.3 EUROPE
13.3.1 GERMANY
13.3.1.1 Expanding GMP capacity and integrated oligonucleotide partnerships are driving Germany’s market growth
13.3.2 UK
13.3.2.1 Strengthening domestic nucleic-acid infrastructure and growing outsourcing demand are driving UK oligonucleotide CDMO growth
13.3.3 FRANCE
13.3.3.1 Strengthening nucleic-acid capabilities and growing outsourcing demand are driving France’s oligonucleotide CDMO market
13.3.4 ITALY
13.3.4.1 Specialized oligonucleotide infrastructure and growing demand for integrated development services are supporting Italy’s market growth
13.3.5 SPAIN
13.3.5.1 Expanding domestic manufacturing infrastructure and institutional support for therapeutic oligonucleotides are driving Spain’s market growth
13.3.6 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 CHINA
13.4.1.1 Expanding integrated manufacturing capacity and strengthening domestic oligonucleotide supply chains are driving China’s market growth
13.4.2 JAPAN
13.4.2.1 Advanced manufacturing capabilities and rising demand for complex oligonucleotide therapeutics are driving Japan’s market growth
13.4.3 INDIA
13.4.3.1 Expanding GMP infrastructure and global outsourcing are driving India’s oligonucleotide CDMO market
13.4.4 AUSTRALIA
13.4.4.1 Expanding domestic manufacturing and growing biopharmaceutical outsourcing are supporting Australia’s oligonucleotide CDMO market
13.4.5 SOUTH KOREA
13.4.5.1 Synthetic biology, organoid-based screening, and AI-enabled discovery to support market growth
13.4.6 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 BRAZIL
13.5.1.1 Infectious-disease research, shared protein-production infrastructure, and vaccine innovation to drive market
13.5.2 MEXICO
13.5.2.1 Nearshoring and expanding regional manufacturing capabilities are supporting Mexico’s oligonucleotide CDMO market
13.5.3 REST OF LATIN AMERICA
13.6 MIDDLE EAST
13.6.1 GCC
13.6.1.1 Saudi Arabia
13.6.1.1.1 Biotechnology localization and expanding genomic medicine capabilities are driving Saudi Arabia’s oligonucleotide CDMO market
13.6.1.2 UAE
13.6.1.2.1 Growing biopharmaceutical activity and need for localized advanced-therapy manufacturing are creating opportunities for UAE’s oligonucleotide CDMO services
13.6.1.3 Rest of GCC Countries
13.6.2 REST OF MIDDLE EAST
13.7 AFRICA
13.7.1 GROWING GENOMICS ACTIVITY AND LIMITED LOCAL MANUFACTURING CAPACITY ARE CREATING OPPORTUNITIES FOR OLIGONUCLEOTIDE CDMO SERVICES ACROSS AFRICA

14.1 INTRODUCTION
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
14.2.1 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE CDMO MARKET, 2023-2026
14.3 REVENUE ANALYSIS
14.4 MARKET SHARE ANALYSIS
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE CDMO MARKET), 2025
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
14.7 COMPETITIVE SCENARIO
14.7.1 PRODUCT APPROVALS
14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
14.9 COMPANY VALUATION AND FINANCIAL METRICS
14.9.1 COMPANY VALUATION AND FINANCIAL METRICS FOR OLIGONUCLEOTIDE CDMO PLAYERS

15.1 KEY PLAYERS
15.1.1 BACHEM INC.
15.1.1.1 Business overview
15.1.1.2 Services offered
15.1.1.3 Recent developments
15.1.1.3.1 Product/Service launches
15.1.1.3.2 Expansions
15.1.1.4 Analyst's view
15.1.1.4.1 Key strengths
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses and competitive threats
15.1.2 THERMO FISHER SCIENTIFIC INC.
15.1.2.1 Business overview
15.1.2.2 Services offered
15.1.2.3 Recent developments
15.1.2.3.1 Product/Service launches
15.1.2.3.2 Expansions
15.1.2.4 Analyst's view
15.1.2.4.1 Key strengths
15.1.2.4.2 Strategic choices
15.1.2.4.3 Weaknesses and competitive threats
15.1.3 AGILENT TECHNOLOGIES, INC.
15.1.3.1 Business overview
15.1.3.2 Services offered
15.1.3.3 Recent developments
15.1.3.3.1 Product/Service launches
15.1.3.3.2 Deals
15.1.3.3.3 Expansions
15.1.3.4 Analyst's view
15.1.3.4.1 Key strengths
15.1.3.4.2 Strategic choices
15.1.3.4.3 Weaknesses and competitive threats
15.1.4 WUXI APPTEC
15.1.4.1 Business overview
15.1.4.2 Services offered
15.1.4.3 Recent developments
15.1.4.3.1 Expansions
15.1.4.4 Analyst's view
15.1.4.4.1 Key strengths/Right to win
15.1.4.4.2 Strategic choices made
15.1.4.4.3 Weaknesses and competitive threats
15.1.5 MARAVAI LIFESCIENCES
15.1.5.1 Business overview
15.1.5.2 Services offered
15.1.5.3 Recent developments
15.1.5.3.1 Deals
15.1.6 LONZA
15.1.6.1 Business overview
15.1.6.2 Services offered
15.1.6.3 Recent developments
15.1.6.3.1 Deals
15.1.6.3.2 Expansions
15.1.7 EUROFINS SCIENTIFIC
15.1.7.1 Business overview
15.1.7.2 Services offered
15.1.7.3 Recent developments
15.1.7.3.1 Expansions
15.1.8 DANAHER CORPORATION
15.1.8.1 Business overview
15.1.8.2 Services offered
15.1.8.3 Recent developments
15.1.8.3.1 Expansions
15.1.8.3.2 Other Developments
15.1.9 GENSCRIPT
15.1.9.1 Business overview
15.1.9.2 Services offered
15.1.9.3 Recent developments
15.1.9.3.1 Expansions
15.1.10 SYNGENE INTERNATIONAL LIMITED
15.1.10.1 Business overview
15.1.10.2 Services offered
15.1.10.3 Recent developments
15.1.10.3.1 Product/Service launches
15.1.10.3.2 Expansions
15.1.11 EUROAPI
15.1.11.1 Business overview
15.1.11.2 Services offered
15.1.11.3 Recent developments
15.1.11.3.1 Deals
15.1.11.3.2 Expansions
15.1.12 AJINOMOTO CO., INC.
15.1.12.1 Business overview
15.1.12.2 Services offered
15.1.12.3 Recent developments
15.1.12.3.1 Expansions
15.1.12.3.2 Deals
15.1.13 ST PHARM
15.1.13.1 Business overview
15.1.13.2 Services offered
15.1.13.3 Recent developments
15.1.13.3.1 Expansions
15.1.13.3.2 Deals
15.1.13.4 Analyst's view
15.1.13.4.1 Key strengths
15.1.13.4.2 Strategic choices
15.1.13.4.3 Weaknesses and competitive threats
15.1.14 KANEKA CORPORATION
15.1.14.1 Business overview
15.1.14.2 Services offered
15.1.15 POLYPEPTIDE GROUP
15.1.15.1 Business overview
15.1.15.2 Services offered
15.1.15.3 Recent developments
15.1.15.3.1 Expansions
15.1.16 AURIGENE PHARMACEUTICAL SERVICES LTD.
15.1.16.1 Business overview
15.1.16.2 Services offered
15.1.17 BIOSPRING
15.1.17.1 Business overview
15.1.17.2 Services offered
15.1.17.3 Recent developments
15.1.17.3.1 Service approvals
15.1.17.3.2 Expansions
15.1.18 NIPPON SHOKUBAI CO., LTD.
15.1.18.1 Business overview
15.1.18.2 Services offered
15.1.18.3 Recent developments
15.1.18.3.1 Service launch
15.1.18.3.2 Expansions
15.1.19 LGC BIOSEARCH TECHNOLOGIES
15.1.19.1 Business overview
15.1.19.2 Services offered
15.1.19.3 Recent developments
15.1.19.3.1 Service launch
15.1.19.3.2 Deals
15.1.19.3.3 Expansions
15.2 OTHER PLAYERS
15.2.1 OLIGO FACTORY
15.2.2 CORDEN PHARMA
15.2.3 BIO-SYNTHESIS, INC.
15.2.4 MICROSYNTH
15.2.5 SYNOLIGO BIOTECHNOLOGIES, INC.
15.2.6 HONGENE BIOTECH CORPORATION
15.2.7 SYLENTIS, S.A.
15.2.8 CREATIVE BIOGENE
15.2.9 NITTO AVECIA
15.2.10 NJ BIO, INC.

16.1 RESEARCH DATA
16.1.1 SECONDARY DATA
16.1.1.1 Key data from secondary sources
16.1.2 PRIMARY DATA
16.1.2.1 Key data from primary sources
16.1.2.2 Key primary participants
16.1.2.3 Breakdown of primary interviews
16.1.2.4 Key industry insights
16.2 MARKET SIZE ESTIMATION
16.2.1 GLOBAL OLIGONUCLEOTIDE CDMO MARKET ESTIMATION, 2025
16.2.2 SEGMENTAL MARKET SIZE ESTIMATION
16.3 MARKET GROWTH RATE PROJECTIONS
16.4 DATA TRIANGULATION
16.5 FACTOR ANALYSIS
16.6 RESEARCH ASSUMPTIONS
16.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT

17.1 DISCUSSION GUIDE
17.2 KNOWLEDGESTORE: THE SUBSCRIPTION PORTAL
17.3 CUSTOMIZATION OPTIONS
17.4 RELATED REPORTS
17.5 AUTHOR DETAILS

TABLE 1 OLIGONUCLEOTIDE CDMO MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
TABLE 3 OLIGONUCLEOTIDE CDMO MARKET: PORTER’S FIVE FORCES
TABLE 4 OLIGONUCLEOTIDE CDMO MARKET: ROLE OF PLAYERS IN ECOSYSTEM
TABLE 5 OLIGONUCLEOTIDE CDMO MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026-JUNE 2027
TABLE 6 RECIPROCAL TARIFF RATES ADJUSTED BY US
TABLE 7 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE CDMO MARKET
TABLE 8 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED OLIGONUCLEOTIDE CDMO TECHNOLOGIES IN OLIGONUCLEOTIDE CDMO MARKET
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,AND OTHER ORGANIZATIONS
TABLE 14 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY SERVICE TYPE
TABLE 15 KEY BUYING CRITERIA, BY END USER
TABLE 16 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 17 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING,BY TYPE, 2024-2031 (USD MILLION)
TABLE 18 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING,BY REGION, 2024-2031 (USD MILLION)
TABLE 19 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 20 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 21 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 22 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 23 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
TABLE 24 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
TABLE 25 OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
TABLE 26 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 27 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 28 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 29 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 30 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
TABLE 31 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
TABLE 32 OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
TABLE 33 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 34 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 35 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 36 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 37 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
TABLE 38 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
TABLE 39 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
TABLE 40 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 41 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 42 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 43 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 44 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
TABLE 45 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
TABLE 46 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY REGION,2024-2031 (USD MILLION)
TABLE 47 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 48 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 49 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 50 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 51 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,BY REGION, 2024-2031 (USD MILLION)
TABLE 52 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,BY REGION, 2024-2031 (USD MILLION)
TABLE 53 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 54 OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 55 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 56 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 57 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 58 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 59 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 60 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 61 OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS,BY REGION, 2024-2031 (USD MILLION)
TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 63 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 66 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 67 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 68 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 69 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 70 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 71 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 72 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 73 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 74 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 75 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 76 OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION,2024-2031 (USD MILLION)
TABLE 77 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ASO,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 78 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 79 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 80 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 81 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION,2024-2031 (USD MILLION)
TABLE 82 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION,2024-2031 (USD MILLION)
TABLE 83 OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION,2024-2031 (USD MILLION)
TABLE 84 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 85 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 86 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 87 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 88 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION,2024-2031 (USD MILLION)
TABLE 89 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA,BY REGION, 2024-2031 (USD MILLION)
TABLE 90 OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY REGION,2024-2031 (USD MILLION)
TABLE 91 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 92 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 93 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 94 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 95 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS,BY REGION, 2024-2031 (USD MILLION)
TABLE 96 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS,BY REGION, 2024-2031 (USD MILLION)
TABLE 97 OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 98 OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 99 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 100 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 101 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 102 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 103 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 104 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 105 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 106 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 107 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 108 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 109 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 110 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 111 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 112 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION,2024-2031 (USD MILLION)
TABLE 113 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 114 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 115 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 116 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 117 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,BY REGION, 2024-2031 (USD MILLION)
TABLE 118 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,BY REGION, 2024-2031 (USD MILLION)
TABLE 119 OLIGONUCLEOTIDE CDMO MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 120 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 121 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 122 NORTH AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 123 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,2024-2031 (USD MILLION)
TABLE 124 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 125 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 126 US: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 127 US: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 128 US: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 129 US: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 130 US: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 131 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 132 CANADA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 133 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,2024-2031 (USD MILLION)
TABLE 134 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 135 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 136 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 137 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 138 EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 139 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,2024-2031 (USD MILLION)
TABLE 140 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 141 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 142 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 143 GERMANY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 144 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,2024-2031 (USD MILLION)
TABLE 145 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 146 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 147 UK: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 148 UK: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 149 UK: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 150 UK: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 151 UK: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 152 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 153 FRANCE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 154 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 155 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 156 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 157 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 158 ITALY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 159 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 160 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 161 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 162 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 163 SPAIN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 164 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 165 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 166 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 167 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 168 REST OF EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 169 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,2024-2031 (USD MILLION)
TABLE 170 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 171 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 173 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 174 ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 175 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,2024-2031 (USD MILLION)
TABLE 176 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 177 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 178 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 179 CHINA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 180 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 181 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 182 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 183 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 184 JAPAN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 185 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 186 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 187 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 188 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 189 INDIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 190 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 191 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 192 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 193 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 194 AUSTRALIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 195 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,2024-2031 (USD MILLION)
TABLE 196 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 197 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 198 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 199 SOUTH KOREA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 200 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,2024-2031 (USD MILLION)
TABLE 201 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 202 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 203 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 204 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 205 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,2024-2031 (USD MILLION)
TABLE 206 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 207 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 208 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 210 LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 211 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,2024-2031 (USD MILLION)
TABLE 212 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 213 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 214 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 215 BRAZIL: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 216 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 217 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 218 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 219 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 220 MEXICO: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 221 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 222 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 223 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 224 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 225 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 226 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET,BY TYPE, 2024-2031 (USD MILLION)
TABLE 227 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET,BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 228 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET,BY END USER, 2024-2031 (USD MILLION)
TABLE 229 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 230 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 231 MIDDLE EAST: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 232 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,2024-2031 (USD MILLION)
TABLE 233 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 234 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 235 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 236 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 237 GCC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 238 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 239 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 240 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 241 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 242 SAUDI ARABIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 243 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,2024-2031 (USD MILLION)
TABLE 244 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 245 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 246 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 247 UAE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 248 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 249 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 250 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 251 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 252 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 253 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET,BY TYPE, 2024-2031 (USD MILLION)
TABLE 254 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET,BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 255 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET,BY END USER, 2024-2031 (USD MILLION)
TABLE 256 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 257 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 258 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,2024-2031 (USD MILLION)
TABLE 259 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 260 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 261 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,2024-2031 (USD MILLION)
TABLE 262 AFRICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,BY SERVICE TYPE, 2024-2031 (USD MILLION)
TABLE 263 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 264 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 265 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 266 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE CDMO MARKET, 2023-2026
TABLE 267 OLIGONUCLEOTIDE CDMO MARKET: DEGREE OF COMPETITION
TABLE 268 OLIGONUCLEOTIDE CDMO MARKET: REGIONAL FOOTPRINT
TABLE 269 OLIGONUCLEOTIDE CDMO MARKET: SERVICE TYPE FOOTPRINT
TABLE 270 OLIGONUCLEOTIDE CDMO MARKET: TYPE FOOTPRINT
TABLE 271 OLIGONUCLEOTIDE CDMO MARKET: APPLICATION FOOTPRINT
TABLE 272 DETAILED LIST OF KEY STARTUPS/SMES
TABLE 273 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 274 OLIGONUCLEOTIDE CDMO MARKET: SERVICE LAUNCHES,JANUARY 2023-JULY 2026
TABLE 275 OLIGONUCLEOTIDE CDMO MARKET: DEALS, JANUARY 2023-JULY 2026
TABLE 276 OLIGONUCLEOTIDE CDMO MARKET: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 277 BACHEM INC.: COMPANY OVERVIEW
TABLE 278 BACHEM INC.: SERVICES OFFERED
TABLE 279 BACHEM INC.: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
TABLE 280 BACHEM INC.: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 281 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 282 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
TABLE 283 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES,JANUARY 2023-JULY 2026
TABLE 284 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 285 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 286 AGILENT TECHNOLOGIES, INC.: SERVICES OFFERED
TABLE 287 AGILENT TECHNOLOGIES, INC.: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
TABLE 288 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023-JULY 2026
TABLE 289 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 290 WUXI APPTEC: COMPANY OVERVIEW
TABLE 291 WUXI APPTEC: SERVICES OFFERED
TABLE 292 WUXI APPTEC: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 293 MARAVAI LIFESCIENCES: COMPANY OVERVIEW
TABLE 294 MARAVAI LIFESCIENCES: SERVICES OFFERED
TABLE 295 MARAVAI LIFESCIENCES: DEALS, JANUARY 2023-JULY 2026
TABLE 296 LONZA: COMPANY OVERVIEW
TABLE 297 LONZA: SERVICES OFFERED
TABLE 298 LONZA: DEALS, JANUARY 2023-JULY 2026
TABLE 299 LONZA: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 300 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 301 EUROFINS SCIENTIFIC: SERVICES OFFERED
TABLE 302 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 303 DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 304 DANAHER CORPORATION: SERVICES OFFERED
TABLE 305 DANAHER CORPORATION: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 306 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
TABLE 307 GENSCRIPT: COMPANY OVERVIEW
TABLE 308 GENSCRIPT: SERVICES OFFERED
TABLE 309 GENSCRIPT: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 310 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
TABLE 311 SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED
TABLE 312 SYNGENE INTERNATIONAL LIMITED: SERVICE LAUNCHES,JANUARY 2023-JULY 2026
TABLE 313 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 314 EUROAPI: COMPANY OVERVIEW
TABLE 315 EUROAPI: SERVICES OFFERED
TABLE 316 EUROAPI: DEALS, JANUARY 2023-JULY 2026
TABLE 317 EUROAPI: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 318 AJINOMOTO CO., INC.: COMPANY OVERVIEW
TABLE 319 AJINOMOTO CO., INC.: SERVICES OFFERED
TABLE 320 AJINOMOTO CO., INC.: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 321 AJINOMOTO CO., INC.: DEALS, JANUARY 2023-JULY 2026
TABLE 322 ST PHARM: COMPANY OVERVIEW
TABLE 323 ST PHARM: SERVICES OFFERED
TABLE 324 ST PHARM: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 325 ST PHARM: DEALS, JANUARY 2023-JULY 2026
TABLE 326 KANEKA CORPORATION: COMPANY OVERVIEW
TABLE 327 KANEKA CORPORATION: SERVICES OFFERED
TABLE 328 POLYPEPTIDE GROUP: COMPANY OVERVIEW
TABLE 329 POLYPEPTIDE GROUP: SERVICES OFFERED
TABLE 330 POLYPEPTIDE GROUP: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 331 AURIGENE PHARMACEUTICAL SERVICES LTD.: COMPANY OVERVIEW
TABLE 332 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICES OFFERED
TABLE 333 BIOSPRING: COMPANY OVERVIEW
TABLE 334 BIOSPRING: SERVICES OFFERED
TABLE 335 BIOSPRING: SERVICE APPROVALS, JANUARY 2023-JULY 2026
TABLE 336 BIOSPRING: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 337 NIPPON SHOKUBAI CO., LTD.: COMPANY OVERVIEW
TABLE 338 NIPPON SHOKUBAI CO., LTD.: SERVICES OFFERED
TABLE 339 NIPPON SHOKUBAI CO., LTD.: SERVICE LAUNCH, JANUARY 2023-JULY 2026
TABLE 340 NIPPON SHOKUBAI CO., LTD.: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 341 LGC BIOSEARCH TECHNOLOGIES: COMPANY OVERVIEW
TABLE 342 LGC BIOSEARCH TECHNOLOGIES: SERVICES OFFERED
TABLE 343 LGC BIOSEARCH TECHNOLOGIES: SERVICE LAUNCH, JANUARY 2023-JULY 2026
TABLE 344 LGC BIOSEARCH TECHNOLOGIES: DEALS, JANUARY 2023-JULY 2026
TABLE 345 LGC BIOSEARCH TECHNOLOGIES: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 346 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 347 RISK ASSESSMENT

FIGURE 1 OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION AND REGIONS CONSIDERED
FIGURE 2 OLIGONUCLEOTIDE CDMO MARKET: YEARS CONSIDERED
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL OLIGONUCLEOTIDE CDMO MARKET, 2024-2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE CDMO MARKET, 2023-2026
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF OLIGONUCLEOTIDE CDMO MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN OLIGONUCLEOTIDE CDMO MARKET, 2026-2031
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN OLIGONUCLEOTIDE CDMO MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9 INCREASING FOCUS ON PRECISION/PERSONALIZED MEDICINE
FIGURE 10 ANTISENSE OLIGONUCLEOTIDES ACCOUNTED FOR LARGEST SHARE OF OLIGONUCLEOTIDE CDMO MARKET IN NORTH AMERICA IN 2025
FIGURE 11 ASIA PACIFIC TO BE FASTEST-GROWING MARKET IN GLOBAL OLIGONUCLEOTIDE CDMO MARKET DURING FORECAST PERIOD
FIGURE 12 CONTRACT MANUFACTURING TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 13 OLIGONUCLEOTIDE CDMO MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 OLIGONUCLEOTIDE CDMO MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15 VALUE CHAIN ANALYSIS
FIGURE 16 OLIGONUCLEOTIDE CDMO MARKET: ECOSYSTEM ANALYSIS
FIGURE 17 OLIGONUCLEOTIDE CDMO MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 18 INVESTMENT AND FUNDING SCENARIO, 2023-2026 (USD MILLION)
FIGURE 19 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET
FIGURE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY SERVICE TYPE
FIGURE 21 KEY BUYING CRITERIA, BY END USER
FIGURE 22 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT
FIGURE 23 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT
FIGURE 24 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE CDMO MARKET, 2021-2025
FIGURE 25 OLIGONUCLEOTIDE CDMO MARKET SHARE ANALYSIS, BY KEY PLAYER, 2025
FIGURE 26 OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2025
FIGURE 27 OLIGONUCLEOTIDE CDMO MARKET: COMPANY FOOTPRINT
FIGURE 28 OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2025
FIGURE 29 BRAND/PRODUCT COMPARATIVE ANALYSIS FOR OLIGONUCLEOTIDE CDMO MARKET, BY COMPANY
FIGURE 30 EV/EBITDA OF KEY VENDORS IN CDMO MARKET
FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS IN OLIGONUCLEOTIDE CDMO MARKET
FIGURE 32 BACHEM INC.: COMPANY SNAPSHOT (2025)
FIGURE 33 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 34 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 35 WUXI APPTEC: COMPANY SNAPSHOT (2025)
FIGURE 36 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2025)
FIGURE 37 LONZA: COMPANY SNAPSHOT (2025)
FIGURE 38 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 40 GENSCRIPT: COMPANY SNAPSHOT (2025)
FIGURE 41 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2025)
FIGURE 42 EUROAPI: COMPANY SNAPSHOT (2025)
FIGURE 43 AJINOMOTO CO., INC.: COMPANY SNAPSHOT (2025)
FIGURE 44 ST PHARM: COMPANY SNAPSHOT (2025)
FIGURE 45 KANEKA CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 46 POLYPEPTIDE GROUP: COMPANY SNAPSHOT (2025)
FIGURE 47 NIPPON SHOKUBAI CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 48 LGC BIOSEARCH TECHNOLOGIES: COMPANY SNAPSHOT (2024)
FIGURE 49 OLIGONUCLEOTIDE CDMO MARKET: RESEARCH DESIGN
FIGURE 50 OLIGONUCLEOTIDE CDMO MARKET: BREAKDOWN OF PRIMARIES
FIGURE 51 OLIGONUCLEOTIDE CDMO MARKET: INSIGHTS FROM PRIMARIES
FIGURE 52 GLOBAL OLIGONUCLEOTIDE CDMO MARKET ESTIMATION, 2025
FIGURE 53 OLIGONUCLEOTIDE CDMO MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025)
FIGURE 54 ILLUSTRATIVE EXAMPLE OF AGILENT TECHNOLOGIES, INC.:REVENUE ANALYSIS (2025)
FIGURE 55 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 56 OLIGONUCLEOTIDE CDMO MARKET: CAGR PROJECTIONS
FIGURE 57 OLIGONUCLEOTIDE CDMO MARKET: DATA TRIANGULATION